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Background: Limited information is available on the epidemiology and economics of bleeding during surgery
in France.
Method: The objective of this study was to examine the incidence, costs and length of stay (LOS) of bleeding-
related complications during various surgical procedures.
A retrospective DRG (diagnosis-related group) analysis was conducted using the French National database PMSI
(Programme Médicalisé des Systèmes d’Informations). Patients undergoing surgery during 2008 were identified
according to their DRG classifications and those with at least one episode of secondary haemostasis and blood
transfusion (according to French procedure codes) were designated as ‘with bleeding’ (WB). The analysis focussed
on DRGs where ≥10% of patients presenting with bleeding and compared them to patients who did not require
blood transfusions (i.e. without bleeding: WoB).
Hospital LOS and costs (age and gender adjusted) were compared between WB and WoB patients within each
DRG. Hospitalisation periods exceeding the LOS average (derived from the PMSI database) were compared using
multivariate logistic regression adjusted for patient characteristics.
Results: Amongst all 88 different surgical DRGs recognised by the French database 24 (totalling 321,657
hospitalisations) yielded WB rates ≥10% (range 10.3–25.3%). The highest DRG rates were for transplantations, cardiac
and major orthopaedic surgery, vascular and solid organ surgery.
The average LOS for the WB population (adjusted for age, gender, number of procedures and secondary diagnoses)
were 3.38 days (26.5%) longer than for the WoB population (p < 0.001). The average adjusted LOS costs for a WB
patient were estimated at €12,087, and for a WoB patient €10,086 i.e. 19.9% higher than for WB patients (p < 0.001).
The overall mean LOS was exceeded by 42.3% of WB patients compared to 37.0% of WoB patients (p < 0.001).
Also, WB patients were more likely to exceed the average LOS than were WoB patients (Odds Ratio (OR) = 1.09,
p < 0.001), after adjusting for patient characteristics.
Conclusions: The present study for France demonstrates a significant increase of hospital LOS and associated costs
following post-surgical bleeding, supporting the need for blood conservation strategies.
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Bleeding is a frequent complication following surgery that
can lead to substantial morbidity and mortality [1,2].
During surgery, or when managing trauma, surgeons may
be faced by mild to severe bleeding necessitating simple or
intricate procedures according to anatomical location, the
proximity of adjacent structures, and type of tissue
harbouring the bleeding source. In such situations surgeons
must decide how best to stem the bleeding using available
products and techniques together or sequentially.
Insufficient haemostasis can increase operative time and
when excessive may need whole blood or blood constituent
transfusions. Further complications include longer hospital-
isation, risk of infection, and ventilation requirement.
Haemostasis is usually performed mechanically (sutures,
ligatures, clips, staples) or with various electrically gener-
ated coagulation systems (electrocautery, argon beam
lasers, ultrasound) [3,4].
Blood transfusions and reoperations are not uncommon
sequellae when excessive bleeding follows surgery, even in
France where blood transfusions have dramatically de-
creased because of AIDS and hepatitis risks [5,6]. Between
1992 and 2001 the French Blood Public Organisation [7]
reported a fall of 2 million (23.6%) blood transfusion units
administered per year. In 2009 the National Blood Bank de-
livered a total of 2.2 million such units in France, with 25%
administered to surgical patients [8] mainly for trauma,
orthopaedic surgery and cardiac surgery.
Post-surgical bleeding complications can create a
significant economic impact. Boucher and Hannon [9]
estimated that haematocyte transfusions in the US cost
from $1,840 to $2,760 per unit, plus operating theatre time
of $1,890 to $3,150, intensive care unit supervision, and
ventilator support, amounting in total to $4,810.
Little information is currently available on bleeding com-
plication rates and related costs in European countries.
Hence the availability of a fairly comprehensive hospital
database in France provides a unique opportunity to exam-
ine this important issue. For the present study we assumed
that bleeding episodes could be identified in the database.
Such information would permit a comparison of hospital-
isation costs both with and without blood loss.
The primary objectives of the present French hospital
database analysis were: (1) to estimate the frequency of
surgical DRGs associated with blood or blood constituent
transfusions administered to ≥10% of WB patients; and (2)
to compare the estimated costs of bleeding episodes and
transfusions required by these patients versus the costs of
WoB patients drawn from similar surgical DRGs.
Methods
French hospital database PMSI-MCO
The French computerised hospital database for medicine,
surgery and obstetrics (PMSI-MCO: Programme Médicalisédes Systèmes d’Informations – Médecine Chirurgie
Obstétrique) covers all short-term hospitalisations in France
(about. 20 million public and private admissions per
annum). It comprises a standardised case record compiled
at discharge after each short-term hospitalisation and
encodes administrative and medical data with standardised
classifications and nomenclatures.
The system is derived from the US DRG classification
and employs a decision tree that leads each hospitalisation
towards its appropriate diagnostic or surgical procedures
group (Groupe Homogène de Malades: GHM). Accessible
data for all patients include age, gender, admission and
discharge addresses, primary and secondary diagnoses,
treatment procedures, DRG codes, admission duration,
intensive care resources deployed, hospital identification,
public or private sector, etc.
Nomenclature adopted the Xth revision of the Inter-
national Classification of Diseases (ICD-10) of the World
Health Organization [10], defining conditions by one
primary diagnosis and up to 20 secondary diagnoses per
hospitalisation, plus the French classification of medical
procedures “La Classification Commune des Actes
Médicaux” (CCAM), available as a full listing [11]. Thus
medico-administrative (PMSI) variables plus one surgical
act were sufficient to classify a hospitalisation as a ‘surgi-
cal’ DRG. After 2004, global hospitalisation budgets were
progressively replaced by new budgets linked to specific
activities (T2A Tarification A l’Activité). The new proced-
ure was fully in place by 2008. Official tariffs per DRG in
French hospitals are revised and issued every 6 months by
the French Ministry of Health [12]. These tariffs per DRG
are charged to the Sickness Funds for each hospitalisation.
These tariffs were not used for our costing.
Study patients
The study was limited to surgery and included patients of
all ages. DRG classification was performed at hospital
discharge in 2008, hence some patients hospitalised in
2007 were included and others not discharged until 2009
were necessarily excluded. All hospitalisations extended to
at least 2 nights. Shorter hospitalisations were less docu-
mented and no death was recorded in these short stays.
Patient inclusion was based on surgical DRGs identified
in the French system by a third letter coding ‘C’ for
surgery (Chirurgie). A surgical procedure was the primary
criterion specifying such DRGs.
Procedures such as aortic aneurysm repair are not
classified as surgery.
Bleeding-related complication and/or blood product
transfusion status
Bleeding-related complications and/or blood product
transfusions were identified according to diagnosis and
procedure codes relating to bleeding complications.
Ye et al. BMC Health Services Research 2013, 13:186 Page 3 of 8
http://www.biomedcentral.com/1472-6963/13/186Patients were divided into two groups, i.e. with bleeding
(WB) or without bleeding (WoB) provided one of the
following codes was retrieved for the hospitalisation: (1)
Procedures codes (i.e. 11 CCAM codes: Additional file 1)
for secondary haemostasis following index surgery
(not preventative transfusions); or (2) one of the four
following ICD Diagnosis codes: T81.0 for haemorrhage or
haematoma complicating a procedure; Z513 for blood
products transfusion; Y63.0 for natural blood and blood
products; and Y446 for transfusion reactions.
It should be noted that no information was available
concerning which blood products were transfused, since
their costs were not included in the database. As diagnoses
and codes for transfusion procedures were confounded,
actual transfusion rates may be underestimated by the lack
of specific coding. Also, surgical patients identified by
bleeding, transfusions, or other haemorrhagic outcomes
may have been coded for a manifestation of their under-
lying condition, or for a complication of surgery, with
no possibility of identifying the real cause of bleeding.
Hence in this manuscript ‘bleeding’ necessarily confounds
bleeding complications and transfusions. Data concerning
pre-operative bleeding risks were not available.
Statistical analysis
Hospitalisations associated with bleeding complications
were extracted for each diagnosis-related group and their
frequencies were ranked across DRGs. Surgical DRGs
presenting where ≥10% of patients presented with bleed-
ing were selected for further analysis. Control patients
were those without bleeding (WoB) drawn from similar
surgical DRGs. The ≥10% criterion was chosen empirically
to include sufficient WB and WoB group sizes for
comparisons of costs and LOS outcomes. DRGs were
merged when they involved patients within the same
organ classification undergoing similar surgical proce-
dures with bleeding differences (<3%) (Additional file 2) to
increase the power of the statistical analysis.
Comparisons of WB and WoB groups within each
merged DRG were based on patient characteristics (age
and gender) and DRG aspects unrelated to the classifi-
cation, e.g., number of procedures and secondary diagno-
ses. Patient groups were compared for age, gender,
number of procedures, number of diagnoses, adjusted
length of stay (LOS) and costs, using non-parametric sta-
tistics (Wilcoxon). Cost estimates were derived from the
French National Costs Scale based on information from a
sample of hospitals using similar accounting methods and
linked to the PMSI. This enabled statistical and economic
analyses to calculate average costs per DRG. Separate
scales were applied to public and private sectors. Cost
estimates per DRG comprised total hospital costs includ-
ing overheads and public sector physicians’ salaries and
private sector physicians’ fees not included in the tariffs.The foregoing standard costs were applied to DRGs
according to the hospital sector. No difference was
observed in the bleeding rates between sectors.
Rates of hospitalisations for WB and WoB surgery
exceeding the PMSI average LOS were compared using
multivariate logistic regression that included confounding
variables. The analysis was kept simple and objective, i.e.
bleeding versus non-bleeding cases. Confounding variables
were selected that primarily permitted comparisons of
DRGs (with and without bleeding) according to patient
characteristics (age and gender), LOS, numbers of diagno-
ses and procedures. Convergence within the model and
statistically significant covariates were checked. No centre
effect was included in the analyses as hospitals belonging
to regional networks could not be precisely identified in
the database.
Prior to comparisons, costs of hospitalisation with and
without bleeding were calculated per surgical group and
complication status. Adjustments for age, gender, num-
bers of procedures and secondary diagnoses were per-
formed for the WB complication groups based on the
difference observed between the WB group and the
WoB group taking the WoB group as the reference.
Transfer of patients to other acute care hospitals was
rare and can be ignored.
Statistical analyses were performed using SAS Statistical
Software #9.2 (SAS Institute Inc., North Carolina, USA)
with a 5% significance threshold for all tests.
Results
Surgical DRGs with and without bleeding
In total, 88 different surgical DRGs resulting in 1,720,486
hospitalisations in 2008 were identified in the French
PMSI database. Hospitalisations with bleeding compli-
cations (defined previously) totalled 77,521 cases (4.5%).
More than 95% of WB cases were identified by at least
one code relating to a transfusion.
Twenty-four surgical DRGs (totalling 321,657 hospita-
lisations) were characterised by ≥10% of patients consi-
dered as with bleeding (Figure 1).
The latter DRGs were combined when their WB rates
and surgical interventions were similar and correspon-
ded to the same organ group. Ten surgical DRGs with
the highest proportion of patients given blood or blood
constituent transfusions are shown in Figure 2.
Hospital LOS and costs
Hospital LOS and costs of surgical DRGs for WB patients
were compared with those of surgical WoB patients.
Figures 3 and 4 depict unadjusted total hospitalisation
durations (LOS) and costs according to surgical group
and complication status. Overall LOS and total hospital
costs are displayed across all surgical groups in Figure 5,
according to surgical group and complication status, with
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Figure 2 Rate of bleeding related consequences (Top 10 surgical groups).
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Figure 3 Costs associated with bleeding related consequences (Top 10 surgical groups) with costs adjusted for the WB group.
Figure 4 LOS (Days) associated with bleeding related consequences (Top 10 surgical groups) with adjusted LOS for the WB group.
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Figure 5 Adjusted mean LOS (p < 0.0001) and Costs (p < 0.0001) according to the WB status.
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performed. On average, surgical LOS was longer for WB
than WoB patients (16.2 vs. 12.9 days) and their respective
costs were higher (€11,984 vs. €10,178) across all DRGs.
Also, unadjusted average LOS was longer for WB than
WoB patients (16.6 vs. 12.9 days) and respective costs
were higher (€12,147 vs. €10,178).
Rate of stays over the LOS mean
Hospitalisations of WB patients were classified as above
or below the mean LOS for every surgical DRG associated
with severe blood loss. A global analysis was then
performed of hospitalisation durations above the LOS
mean, comparing percentages of WB and WoB patients
across all DRGs. The results are shown in Figure 6.
A global statistical analysis was performed by logistic
regression adjusted for patients’ characteristics. The modelFigure 6 Percentages exceeding average LOS.included 321,657 observations with 121,147 LOS dura-
tions exceeding the overall hospitalisation mean. Five
characteristics were included in the model, i.e. patients’
age (<65 to >80), gender, number of surgical procedures
(<6, 6–12, >12), number of secondary diagnoses (<3, 3–5,
>6) and bleeding (Yes/No, i.e. WB or WoB). Characteris-
tics’ classes were defined empirically to have sufficient
sample sizes in each group of each DRG. The model
(Table 1) was convergent and all tested variable were
included.
The logistic regression global analysis showed that
surgical hospitalisations of WB patients posed a signi-
ficantly higher risk (p < 0.001) of exceeding average
hospital LOS durations, compared to cases with no
transfusion (OR: 1.09; 95% CI: 1.07-1.11). In addition,
other independent variables were also significant. For
example, hospitalisations involving >12 surgical
Table 1 Odd ratios estimates of the logistic regression model
Effect Point estimate 95% confidence interval de Wald
Gender Female vs Male 1.137 1.120 1.155
Age class >80 years vs <65 years 1.189 1.166 1.213
65–70 vs <65 years 1.234 1.202 1.266
>70–75 vs <65 years 1.249 1.220 1.279
>75–80 vs <65 years 1.394 1.363 1.426
Bleeding Yes vs No 1.060 1.037 1.083
Number of procedures >12 procedures vs <6 procedures 1.966 1.926 2.007
6–12 vs <6 procedures 1.234 1.210 1.259
Number of secondary diagnoses (DAS) >6 DAS vs <3 DAS 1.129 1.107 1.152
3–6 DAS vs <3 DAS 1.001 0.984 1.019
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risk of exceeding the average LOS, compared to <6
procedures.
Discussion
Our results indicate that bleeding events during major
surgery in France (2008) requiring blood or constituent
transfusions were relatively common, although fre-
quencies varied between DRG classes. The three DRG
combinations most frequently associated with blood
transfusions were heart transplants (25.2%), major hip/
knee and multiple orthopaedic interventions (24.7%), and
pulmonary transplants (24.0%).
In general, surgical patients requiring blood trans-
fusions were more frequently female, elderly and liable
to more secondary diagnoses. Also DRGs involving nu-
merous surgical procedures were more often associated
with blood transfusions requirements. After adjustment
for age, gender, number of procedures and secondary
diagnoses, longer hospital admissions and higher costs
characterised surgical DRGs, with ≥10% of patients given
blood or blood constituent transfusions. When assessing
the LOS durations of WB patients we were obliged to
perform indirect analyses based on LOS frequencies in
excess of DRG averages, so as to accommodate the
French algorithm determining DRG codes. Hospital LOS
is an important factor when determining DRG codes.
The presence of bleeding complications can lead to
more severe and more costly DRGs on account of se-
condary diagnoses and longer LOS durations. Although
longer hospitalisations automatically lead to more severe
DRGs, this does not imply a direct linkage between hos-
pital LOS and surgical procedure costs, with or without
bleeding complications. Indeed, a rapid and fatal compli-
cation could direct a patient’s diagnosis to a less severe
DRG because the LOS was insufficiently long.
Very few papers have explored the clinical and eco-
nomic consequences of severe bleeding during surgery.
Most have focussed on how to reduce the need for bloodtransfusion by screening for anaemia and treating
affected patients with erythropoietin stimulating agents,
as before elective orthopaedic surgery. We identified a
recent US analysis by Morton et al. [13] which estimated
the increase in average LOS at 2.5 days and found that
costs were $17 194 higher for a transfused cohort com-
pared to controls (p < 0.0001). However, there are many
reasons for caution, e.g., transfusion data in the US study
may have been more complete than reported here for
France, i.e. the US difference was based on all hospi-
talisations, instead of selected hospitalisations in our
study which used a different design; differences between
the US and French Healthcare systems also exist in terms
of medical practice, hospitalisation durations, and costs.
Nonetheless, both studies point to similar conclusions
in terms of higher costs associated with bleeding
complications.
The present study has several limitations. First, in the
absence of a specific directive and hospital record code,
whole blood and blood constituent charges are not for-
mally included in the database, hence it is probable that
transfusion frequency and costs were under-estimated.
This is supported by the following estimate for the
77,521 surgical patients in the present study. A ‘one day’
national survey in 2008 identified 742 surgical patients
transfused with a total of 5,765 erythrocyte units,
i.e. 7.8 units / patient [8]. Accordingly, the 77,521
surgical patients in the present study would have re-
ceived a total of 7.8 × 77,521 = 604,663 erythrocyte units.
The latter number, however, amounts to just one-third of
the 2,013,863 erythrocytes units transfused in French
hospitals during 2006 [7]: i.e. 2,013,863 / 604,663 = 3.3.
This bias could be important but should in fact under-
estimate the difference in costs and LOS as a part of
patients with bleeding but not coded so and were
included in the WoB group.
Second, because our analysis was retrospective, unre-
ported factors may have confounded relationships bet-
ween surgical bleeding consequences, LOS, and costs.
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mation, hence costs were estimated from the National
costs scales and an application of average costs to
surgical DRGs associated with severe blood loss. This
limitation did not allow us to take into consideration the
specific distributions of costs and LOS.
Fourth, French hospital networks are providing pooled
information on their hospitals that does not allow taking
into account a centre effect and to study relationship of
hospital characteristics and costs with bleeding rates.
Fifth, the methods that we selected could have some
impact on our results. Our age groups were large, espe-
cially for the younger patients. Even, if paediatric cases
were very rare (less than 1%) younger adults could pre-
sent less frequently bleeding and require less transfu-
sions middle age patients and this could have biased our
estimates. Lastly, we did not analyse the influence of the
sector on the costs consequences of bleeding because
we thought it could be redundant with the patient’s
characteristics.
Then, it appears that our study can be considered as a
pilot study because of the possible important bias that
could have underestimate of overestimate our LOS and
costs results. Further and more precise analyses are
needed to confirm our results in France as similar stu-
dies could also be performed in other countries where
DRG systems and costs could be different and lead to
other conclusions.
Conclusion
In conclusion, this study estimated increases of hospital
LOS and costs for patients with severe surgical blee-
ding complications in France. Hospitalisations longer
than the average LOS across all DRGs indicated
significant costs associated with severe post-surgical
bleeding. Awareness of the clinical and economic con-
sequences of severe post-surgical bleeding provides an
important framework when evaluating blood conserva-
tion strategies.
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combined when they involved similar surgery with similar bleeding
frequencies (differences <3%).
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